Nanobiotix S.A. Actions au Port. EO -,03
- BID
34.3
- ASK
35
- 60 Units60 Units
- 07/24, 07:32:36 AM
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
620.59%
Market Cap
161.32 Mil.
P/E Ratio
0.00
Dividend Yield
0.00 %
Earnings per Share
-0.50 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | ||
| LAST PRICE | 34.3 G | 0 Units |
| PRICE DETERMINATION TIME | 07/24/2026 / 07:32:45 AM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 34.3 | 34.3 |
| PREV. DAY'S PRICE | 34.3 | (07/23) |
| CHANGE DAY BEFORE | +0.00 | 0.00 % |
| 52 WEEK HIGH / LOW | 47.58 (05/14) | 4.76 (07/24) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | -1.08 | -1.44 | -0.50 | -0.38 | -0.34 |
DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
DIVIDEND YIELD IN % | 0.00 % | 0.00 % | 0.00 % | - | - |
DIVIDEND GROWTH IN % | - | - | - | - | - |
PRICE - EARNINGS RATIO | - | - | - | - | - |
PRICE - BOOK RATIO | - | - | - | - | - |
PRICE - SALES RATIO | 8.16 | - | 31.46 | - | - |
PRICE - CASH FLOW RATIO | - | - | - | - | - |
Master Data
| WKN | A1J7EB |
| ISIN | FR0011341205 |
| SYMBOL | 5NR |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | NANOBIOTIX INH. EO-,03 |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | - |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | - |
| MARKET CAPITALISATION | 161.32 Mil. |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | 3.88 % | 11.44 % | 21.37 % | 92.70 % | 620.59 % | 374.41 % | 195.18 % | 79.58 % |
| HIGH | 35.88 | 37.28 | 47.58 | 47.58 | 47.58 | 47.58 | 47.58 | 47.58 |
| LOW | 30.56 | 28.90 | 26.44 | 17.02 | 4.76 | 2.66 | 1.60 | 16.70 |
Dividende
pro Aktie
NANOBIOTIX INH. EO-,03 does not deliver dividend information
Company profile
Nanobiotix SA is a late-stage biotechnology company, which engages in the development of therapeutic approaches to the treatment of cancer. Its technologies include NanoXray that improves the efficacy of radiation therapy against tumor cells. The company was founded by Laurent Lévy and Abdel Kader Boussaha on March 4, 2003 and is headquartered in Paris, France.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.